May 2019 Update on GeoVax Labs, Inc. (GOVXD-OTC)

Posted by Karen Goldfarb

May 28, 2019 at 12:27 PM

GeoVax.pngCrystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVXD-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Download Update

Snapshot of GeoVax

Cover Image Update 05-28-19

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies using its novel viral vector platform technology and expertise against cancer and infectious diseases. The Company is focused on advancing its promising immunotherapy products into clinical development over the next 12 to 24 months. GeoVax’s Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) technology represents the foundation for producing non-infectious virus-like particles (VLPs) from the cells of the individual receiving the vaccine. Producing VLPs within a vaccinated individual mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection, should it appear, while maintaining the safety characteristics of a replication-defective vector. As a result, the Company has broadly validated the application of its technology and expertise, reflected in a strong and growing portfolio of patented vaccines. GeoVax is developing vaccines in cancer immunotherapy (immuno-oncology) to treat chronic Hepatitis B virus (HBV) infection and against hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa), Zika virus (ZIKV), malaria, and human immunodeficiency virus (HIV). The Company is also developing a therapeutic vaccine for human papillomavirus (HPV) infection, with a specific focus on head and neck cancer (HNC). GeoVax believes its expertise is complementary to a range of other human diseases for which there is an unmet medical need, with plans to expand its pipeline, leveraging its technology and expertise in conjunction with high-value collaborations. The Company’s primary focus is to advance its immuno-oncology programs into clinical development, demonstrating the high commercial potential of GeoVax technology and expertise.

Key Points of GeoVax's Business

  • GeoVax’s most advanced vaccine program is focused on preventing the clade B subtype of HIV prevalent in the larger commercial markets of the Americas, Western Europe, Japan, and Australia. This program is undergoing human clinical trials in the U.S. with support from NIH/NIAID. Also, in seeking to develop a functional cure for HIV, the Company has a collaboration with American Gene Technologies International, Inc. (AGT) to use its vaccine in combination with AGT’s gene therapy, which is on track to enter human clinical trials sponsored by AGT during the second half of 2019.
  • GeoVax began its work within the field of immuno-oncology with a single program for tumor-associated MUC1 vaccines in collaboration with the University of Pittsburgh and ViaMune. During 2018, GeoVax added four additional collaborations to expand its presence within this space: (1) Vaxeal Holding SA (Cyclin B1 tumor-associated antigen), (2) Emory University (HPV-related head and neck cancers), (3) Virometix AG (also for HPV-related cancers), and (4) Leidos, Inc. (multiple potential cancer targets).
  • GeoVax and Enesi Pharma have recently collaborated to develop solid-dose needle-free vaccine formulations utilizing GeoVax’s MVA-VLP vaccine platform combined with Enesi’s ImplaVax® technology. The collaboration is expected to include development of thermostable solid-dose needle-free vaccines for a variety of infectious diseases and evaluation of the potential to generate improved vaccine responses with simplified administration and reduced storage and distribution costs.
  • GeoVax’s short-term goals include entering clinical development for at least one (or perhaps more), of its development programs within the next 12 to 18 months, expanding and building upon its HIV clinical trials. In this time, the Company expects to restructure its equity capital, including attaining new capital investment, and achieving an up-listing of its shares (perhaps to NASDAQ), which would support and sustain the level of investment needed to proceed into human clinical trials.

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic